Prosecution Insights
Last updated: April 19, 2026

Pact Pharma Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
1
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18332169 METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY REDDIG, PETER J 1646 Final Rejection Jun 09, 2023
18306927 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY LEE, YIE CHIA 1642 Non-Final OA Apr 25, 2023
17487411 PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES TIWARI, VYOMA SHUBHAM 1634 Non-Final OA Sep 28, 2021

Managing Pact Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month